1. Cancer Biology
  2. Stem Cells and Regenerative Medicine
Download icon

Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation

  1. Chee Wai Chua
  2. Nusrat J Epsi
  3. Eva Y Leung
  4. Shouhong Xuan
  5. Ming Lei
  6. Bo I Li
  7. Sarah K Bergren
  8. Hanina Hibshoosh
  9. Antonina Mitrofanova
  10. Michael M Shen  Is a corresponding author
  1. Columbia University Medical Center, United States
  2. Rutgers, The State University of New Jersey, United States
Research Article
  • Cited 13
  • Views 2,614
  • Annotations
Cite this article as: eLife 2018;7:e28768 doi: 10.7554/eLife.28768

Abstract

Master regulatory genes of tissue specification play key roles in stem/progenitor cells and are often important in cancer. In the prostate, androgen receptor (AR) is a master regulator essential for development and tumorigenesis, but its specific functions in prostate stem/progenitor cells have not been elucidated. We have investigated AR function in CARNs (CAstration-Resistant Nkx3.1-expressing cells), a luminal stem/progenitor that functions in prostate regeneration. Using genetically-engineered mouse models and novel prostate epithelial cell lines, we find that progenitor properties of CARNs are largely unaffected by AR deletion, apart from decreased proliferation in vivo. Furthermore, AR loss suppresses tumor formation after deletion of the Pten tumor suppressor in CARNs; however, combined Pten deletion and activation of oncogenic Kras results in AR-negative tumors with focal neuroendocrine differentiation. Our findings show that AR modulates specific progenitor properties of CARNs, including their ability to serve as a cell of origin for prostate cancer.

Data availability

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Chee Wai Chua

    Department of Medicine, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Nusrat J Epsi

    Department of Health Informatics, Rutgers, The State University of New Jersey, Newark, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5363-075X
  3. Eva Y Leung

    Department of Medicine, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Shouhong Xuan

    Department of Medicine, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Ming Lei

    Department of Medicine, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Bo I Li

    Department of Medicine, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Sarah K Bergren

    Department of Medicine, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Hanina Hibshoosh

    Department of Pathology and Cell Biology, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Antonina Mitrofanova

    Department of Health Informatics, Rutgers, The State University of New Jersey, Newark, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Michael M Shen

    Department of Medicine, Columbia University Medical Center, New York, United States
    For correspondence
    mshen@columbia.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4042-1657

Funding

National Institute of Diabetes and Digestive and Kidney Diseases (DK076602)

  • Michael M Shen

National Cancer Institute (CA1966692)

  • Michael M Shen

U.S. Department of Defense (Prostate Cancer Research Program PC101820)

  • Chee Wai Chua

U.S. Department of Defense (Prostate Cancer Research Program PC141064)

  • Bo I Li

Prostate Cancer Foundation

  • Michael M Shen

Rutgers SHP Dean's Intramural Grant

  • Antonina Mitrofanova

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments were performed under protocol AAAR9408, which was approved by the Institutional Animal Care and Use Committee at Columbia University Medical Center.

Human subjects: Radical prostatectomy samples were obtained from consented patients under the auspices of an Institutional Review Board approved protocol AAAC4997 at Columbia University Medical Center.

Reviewing Editor

  1. Sean J Morrison, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, United States

Publication history

  1. Received: May 18, 2017
  2. Accepted: January 12, 2018
  3. Accepted Manuscript published: January 15, 2018 (version 1)
  4. Version of Record published: February 9, 2018 (version 2)
  5. Version of Record updated: February 15, 2018 (version 3)

Copyright

© 2018, Chua et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,614
    Page views
  • 450
    Downloads
  • 13
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Cancer Biology
    2. Cell Biology
    Lauren K Williams et al.
    Research Article Updated

    The abscission checkpoint regulates the ESCRT membrane fission machinery and thereby delays cytokinetic abscission to protect genomic integrity in response to residual mitotic errors. The checkpoint is maintained by Aurora B kinase, which phosphorylates multiple targets, including CHMP4C, a regulatory ESCRT-III subunit necessary for this checkpoint. We now report the discovery that cytoplasmic abscission checkpoint bodies (ACBs) containing phospho-Aurora B and tri-phospho-CHMP4C develop during an active checkpoint. ACBs are derived from mitotic interchromatin granules, transient mitotic structures whose components are housed in splicing-related nuclear speckles during interphase. ACB formation requires CHMP4C, and the ESCRT factor ALIX also contributes. ACB formation is conserved across cell types and under multiple circumstances that activate the checkpoint. Finally, ACBs retain a population of ALIX, and their presence correlates with delayed abscission and delayed recruitment of ALIX to the midbody where it would normally promote abscission. Thus, a cytoplasmic mechanism helps regulate midbody machinery to delay abscission.

    1. Cancer Biology
    Luca Tirinato et al.
    Research Article

    Although much progress has been made in cancer treatment, the molecular mechanisms underlying cancer radioresistance (RR) as well as the biological signatures of radioresistant cancer cells still need to be clarified. In this regard, we discovered that breast, bladder, lung, neuroglioma and prostate 6 Gy X-ray resistant cancer cells were characterized by an increase of Lipid Droplet (LD) number and that the cells containing highest LDs showed the highest clonogenic potential after irradiation. Moreover, we observed that LD content was tightly connected with the iron metabolism and in particular with the presence of the ferritin heavy chain (FTH1). In fact, breast and lung cancer cells silenced for the FTH1 gene showed a reduction in the LD numbers and, by consequence, became radiosensitive. FTH1 overexpression as well as iron-chelating treatment by Deferoxamine were able to restore the LD amount and RR. Overall, these results provide evidence of a novel mechanism behind RR in which LDs and FTH1 are tightly connected to each other, a synergistic effect which might be worth deeply investigating in order to make cancer cells more radiosensitive and improve the efficacy of radiation treatments.